ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Saturday, November 7, 2020

9:00AM-11:00AM: Abstract Number: 0909

Residual Disease Activity in Psoriatic Arthritis Patients Treated with Secukinumab and Adalimumab Who Achieved Remission or Low Disease Activity: Results from a Phase 3b, Randomized, Double-blinded, Active-controlled, Head-to-head Study

Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II

9:00AM-11:00AM: Abstract Number: 0863

Residual Treatment Burden, Desired Improvement, and Prioritized Treatment Goals in Systemic Lupus Erythematosus (SLE): Results from the SLE-UPDATE (Understanding Preferences, Disease Activity and Treatment Expectations) Survey in the United States

SLE – Treatment Poster I

9:00AM-11:00AM: Abstract Number: 0714

Response to Abatacept in JIA Categories: Results from the PRCSG/PRINTO JIA Abatacept Phase IV Registry

Pediatric Rheumatology – Clinical Poster II: JIA

9:00AM-11:00AM: Abstract Number: 0904

Response to Ixekizumab by C-reactive Protein Level in Patients with Radiographic Axial Spondyloarthritis: Results from the COAST-V (Biological-Naïve) and COAST-W (TNF Inhibitor-Experienced) Trials at 52 Weeks

Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II

9:00AM-11:00AM: Abstract Number: 0869

Retinal Toxicity in a Multinational Inception Cohort of Systemic Lupus Patients on Hydroxychloroquine

SLE – Treatment Poster I

9:00AM-11:00AM: Abstract Number: 0567

Rheumatologist’s Perception of the Efficacy, Safety and Willingness to Prescribe Infliximab and Use Alternate Drug Supply Programs to Lower Cost of Rheumatoid Arthritis Care

Health Services Research Poster

9:00AM-11:00AM: Abstract Number: 0615

Rheumatology Going Digital: Developing a Rheumatology App for Use by All Patients Attending Our Department to Aid Remote Working and Self-management

Health Services Research Poster

9:00AM-11:00AM: Abstract Number: 0636

Rheumatology Patient Experience and Trends During the SARS-COV-2 Pandemic

Infection-related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 0788

Rigorous Plasma Microbiome Analysis Method Enables Disease Association Discovery

RA – Etiology & Pathogenesis Poster

9:00AM-11:00AM: Abstract Number: 0561

Risk Factors for Falls Among Individuals with Knee OA: A Longitudinal Community-based Study

Epidemiology & Public Health Poster II: OA, Osteoporosis, & Other Rheumatic Disease

9:00AM-11:00AM: Abstract Number: 0926

Risk Factors for Fractures and Osteoporosis Among Patients with Systemic Sclerosis in a United States Cohort

Systemic Sclerosis & Related Disorders – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 0544

Risk Factors for Lumbar Vertebral Osteoporosis Do Not Reflect Factors Traditionally Associated with Osteoporosis at the Hip

Epidemiology & Public Health Poster II: OA, Osteoporosis, & Other Rheumatic Disease

9:00AM-11:00AM: Abstract Number: 0670

Risk Factors for Pseudogout: An Electronic Medical Record Case-Control Study

Metabolic & Crystal Arthropathies Poster

9:00AM-11:00AM: Abstract Number: 0579

Risk Factors of Nonadherence in New Rheumatoid Arthritis Patients

Health Services Research Poster

9:00AM-11:00AM: Abstract Number: 0540

Risk of Hydroxychloroquine Retinopathy in the Community

Epidemiology & Public Health Poster II: OA, Osteoporosis, & Other Rheumatic Disease

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].